The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

Share Price Information for Netscientific (NSCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 63.50
Bid: 62.00
Ask: 65.00
Change: 1.00 (1.60%)
Spread: 3.00 (4.839%)
Open: 62.50
High: 63.50
Low: 62.50
Prev. Close: 62.50
NSCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EMV C leads £4.2m round in 5G and SATCOM leader

29 Nov 2022 07:00

RNS Number : 8492H
NetScientific PLC
29 November 2022
 

Reach: 07.00, 29 November 2022

 

NetScientific plc

 

("NetScientific" or the "Company")

 

EMV Capital leads £4.2m investment round in Scottish 5G and SATCOM leader

 

Sofant Technologies also announces contract with Fortune Global 500 defence company

 

London, UK - 29 November 2022: NetScientific plc (AIM: NSCI), the active international holding company which invests in, develops, and commercialises life sciences/healthcare, sustainability, and technology companies, announces that it has joined an investment round led by its subsidiary EMV Capital Ltd ("EMVC"), together with Scottish Enterprise, Kelvin Capital Limited, and The Future Fund, in Edinburgh based Sofant Technologies Ltd ("Sofant"). The final close took the total joint investment round to £4.2m. This utilises the Company's capital light investment model, including c. £0.3m of investment from NetScientific through convertible loans converting at a discount into this round, and £1.6m of investment from investors introduced by EMVC, including both direct equity and convertible loans.

 

Sofant has also announced a contract with a Fortune Global 500 defence company to support the development of a next-generation tactical communication system.

 

Sofant will use the proceeds from this investment round to build a satellite communications terminal which targets mobile applications during the first half of 2023, and with commercial sales expected to begin later in the year. During the past year, Sofant has doubled the size of its team and achieved several significant technical and commercial milestones which have cleared the pathway to market.

 

Sofant is building a proprietary, highly efficient radio platform that directly addresses the most difficult challenges facing future wireless communication systems. While Sofant is targeting satellite communications and terrestrial fifth-generation (5G) telecommunications where power consumption is reduced by more than 70%, it has now also demonstrated the relevance of its technology to national security applications.

 

Dr Ilian Iliev, CEO of NetScientific and Sofant Board member, said that:

 

"We are delighted with Sofant's tremendous progress in their development roadmap. They continue to make a key contribution to the UK's space tech and telecoms sectors by developing a key component for increased resilience and energy efficiency in SatComs and other telecommunications systems.

 

"We also congratulate Sofant on their first commercial agreement with a leading defence contractor, as global awareness of the critical importance of communications to national security increases. We expect Sofant to play a significant role in future communication systems and are very pleased that its value is already recognised by industry leaders."

 

David Wither, CEO of Sofant, added:

 

"We are very pleased to have investors who understand the disruptive nature of Sofant's technology. When Sofant closed the previous funding round we told our investors we would demonstrate our core technology, which occurred in June of 2022. Sofant will use the proceeds from this investment round to build a satellite communications terminal which targets mobile applications, with commercial sales expected to begin later in the year."

 

This investment will result in the direct equity holding in Sofant by NetScientific of 1.8% at an aggregate value of £0.4m based on this funding round, in addition to EMVC's Capital Under Advisory representing 27.2%.

 

-Ends-

 

For more information, please contact:

 

NetScientific

Ilian Iliev, CEO Via Belvedere Communications

 

WH Ireland (NOMAD, Financial Adviser and Broker)

Chris Fielding / Darshan Patel / Enzo Aliaj +44 (0)20 7220 1666

 

Belvedere Communications

John West / Llew Angus +44 (0) 203 008 6864

Email: langus@belvederepr.com

 

About NetScientific

 

NetScientific Plc ("NSCI") is an active holding Company that proactively invests in a global portfolio of companies across the healthcare, life science, ESG, and deep technology sectors. NetScientific delivers shareholder returns through a proactive and hands-on management approach to its portfolio companies; identifying, investing in, and helping to build game-changing companies. The Group targets value inflection points and the release of value through partial or full exits from trade sales, public listings, or equity sales. The Company has a strong Trans-Atlantic and growing international presence, providing attractive expansion prospects.

 

The Company differentiates itself by employing a capital-light investment approach, making use of its wholly owned subsidiary, EMV Capital's network of private, corporate, and institutional investors. By syndicating investment and making minimal use of its balance sheet, the Company is able to secure direct stakes, as well as carried interest stakes, in its portfolio. This ultimately creates a structure that can support a large portfolio with a limited balance sheet.

 

NetScientific is headquartered in London, United Kingdom, and was admitted to trading on AIM, a market operated by the London Stock Exchange, in 2013.

 

www.netscientific.net

 

About Sofant Technologies

 

Sofant Technologies is a leading-edge radio technology company based in Edinburgh, Scotland. The company is applying its proprietary RF MEMS technology to develop an extremely low power, low-cost platform which solves power consumption and heat problems in satellite communications and 5G antenna systems. Sofant employs a fabless semiconductor business model which enables it to leverage long established high-volume, low-cost production methods. This positions Sofant to offer its customers game-changing performance at a highly competitive price and guaranteed scalability.

 

www.sofant.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAFFFLLLFLTFIF
Date   Source Headline
26th Oct 201612:30 pmRNSVortex Biosciences Appoints Non-Executive Director
30th Sep 20167:00 amRNSProAxsis Gains CE Mark for its Respiratory Test
27th Sep 20167:00 amRNSNetScientific Interim Results
23rd Sep 20167:00 amRNSWanda Technology Selected by 24Hr HomeCare
12th Sep 20167:00 amRNSGlycotest strengthens IP portfolio
8th Sep 20167:00 amRNSWanda Appoints Digital Health Non-Exec Director
6th Sep 20167:00 amRNSNotice of Interim Results
19th Aug 20167:00 amRNSWanda Launches First Consumer App
18th Aug 20167:06 amRNSVortex Biosciences Appoints Experts to New SAB
3rd Aug 20167:00 amRNSVortex Licenses Patents From Harvard University
28th Jul 20167:00 amRNSChange of Adviser
27th Jul 20167:00 amRNSWanda Appoints Medical Director
22nd Jul 20167:00 amRNSA to Z Home Health Care selects Wanda technologies
27th Jun 20167:00 amRNSGrant of Options to Director
15th Jun 20162:13 pmRNSResult of AGM
14th Jun 20167:00 amRNSVortex Biosciences appoints Chairman of SAB
14th Jun 20167:00 amRNSNetScientific hosts Capital Markets Day
10th Jun 20167:30 amRNSConfirmed Start Date for Ian Postlethwaite as CFO
7th Jun 20167:00 amRNSPortfolio PDS Biotechnology presents at BIO 2016
23rd May 20169:00 amRNSNotice of AGM
18th Apr 20167:00 amRNSNetScientific's Vortex presents data at AACR
13th Apr 20167:00 amRNSPDS Biotechnology Reports Positive Phase 1 Results
7th Apr 20167:00 amRNSAnnual Financial Report
5th Apr 20167:00 amRNSNetscientific Appoints Ian Postlethwaite as CFO
30th Mar 20167:00 amRNSProAxsis Forms Scientific Advisory Board
24th Mar 20167:00 amRNSNotice of Results
16th Mar 20167:00 amRNSWanda Forms Scientific Advisory Board
7th Mar 20162:00 pmRNSAdoption of reduced disclosure framework
1st Mar 20161:00 pmRNSVortex co-founder receives US Presidential award
29th Feb 20167:00 amRNSWanda and Dignity Health launch OncoVerse platform
17th Feb 20167:00 amRNSNetScientific appoints Prof. Stephen Smith as NED
9th Feb 201611:05 amRNSPDS Biotechnology partners with NCI
8th Feb 20163:14 pmRNSGrant of Options to Director
26th Jan 20167:00 amRNSDirectorate Change
20th Jan 201611:09 amRNSPDS Biotechnology adds drug development executives
6th Jan 20167:00 amRNSGlycotest Inc. appoints medical advisory board
4th Jan 20167:00 amRNSWANDA signs contract with HRS
16th Dec 20157:00 amRNSLawrence Cohen appointed as CEO of Glycotest Inc.
14th Dec 20157:00 amRNSAppointment of Gene Walther as Vortex CEO
3rd Dec 20157:00 amRNSProAxsis' ProteaseTagT research update
30th Nov 20157:00 amRNSProAxsis presents data to validate its immunoassay
16th Nov 20157:00 amRNSIssue of Equity
11th Nov 20157:00 amRNSHolding(s) in Company
10th Nov 20157:00 amRNSGrant of Options
6th Nov 201512:14 pmRNSResult of General Meeting
3rd Nov 20154:29 pmRNSHolding(s) in Company
21st Oct 20151:52 pmRNSPosting of Circular
1st Oct 20157:00 amRNSProposed Placing and Fund Raising to raise c.£20m
1st Oct 20157:00 amRNSHalf Yearly Report
18th Sep 20157:00 amRNSDivestment of Shareholding in Frontier BioSciences

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.